Maziar Mahjoobi, DO
Interventional Cardiology · Denison, TXNPI 1821123969
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Inari Medical, Inc. accounts for 71.4% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2022 at $32,442 and has fallen 86.2% since, to $4,463 in 2025. Among interventional cardiology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 791 payments — averaging $121.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$69K
- Medtronic$7K
- Abbott$3K
- Boston Scientific$3K
- Terumo Medical Corporation$2K
- Abiomed$1K
- plus $12K from 54 others
Across 22 payments — averaging $1417.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$31K
What the payments were for
- Consulting fees$39,65041%
- Speaking & faculty fees$24,00025%
- Travel & lodging$8,2499%
- Food & beverage$22,89324%
- Education$1,3941%
- Gifts$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CT THROMBECTOMY SYSTEM KIT$81,651
- FLOWTRIEVER CATHETER, S$53,613
- COREVALVE EVOLUT R$1,908
- Watchman$1,690
- AMPLATZER AMULET$1,397
- NRG needle$1,082
- Azur CX Detachable$931
- Artis pheno$892
- CoreValve Evolut$734
- MitraClip$693
- Impella$585
- GLIDESHEATH SLENDER$463
- CHROMOPHARE F300$354
- LEQVIO$268
- Vascular Lithotripsy$225
- WATCHMAN Access System$149
- CAMZYOS$133
- Attruby$125
- (1661) Clin Edu IGT$124
- Cleerly Ischemia$124
How this compares
$96,261 in reported general payments places this provider in the 90th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 610 | $643,246 |
| XareltoRivaroxaban | 216 | $178,642 |
| EntrestoSacubitril/Valsartan | 165 | $149,209 |
| Repatha SureclickEvolocumab | 95 | $92,837 |
| FarxigaDapagliflozin Propanediol | 84 | $57,345 |
| Ranolazine ErRanolazine | 364 | $33,629 |
| JardianceEmpagliflozin | 29 | $27,777 |
| BrilintaTicagrelor | 48 | $24,947 |
| VerquvoVericiguat | 16 | $14,203 |
| Repatha SyringeEvolocumab | 18 | $13,541 |
| ClopidogrelClopidogrel Bisulfate | 1,000 | $10,422 |
| Metoprolol Succinate | 779 | $9,279 |
| Praluent PenAlirocumab | 12 | $8,955 |
| Rosuvastatin Calcium | 664 | $6,520 |
| NexletolBempedoic Acid | 14 | $5,542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $636 | $643,246610 claims |
| Johnson & JohnsonXarelto | $311 | $178,642216 claims |
| NovartisEntresto | $1,039 | $149,209165 claims |
| AstraZenecaFarxiga, Brilinta | $315 | $82,292132 claims |
| Boehringer IngelheimJardiance | $84 | $27,77729 claims |
| MerckVerquvo | $629 | $14,20316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Denison
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
- Peter MonteleoneKyle$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.